Last update Sept. 23, 2023
Very High Risk
A synthetic steroid with antigonadotropic and antiestrogenic activity due to the suppression of the pituitary gland’s gonadotropic hormone and with androgenic effects (Sanofi 2017, AEMPS 2017). Used to treat endometriosis, fibrocystic breast disease, hereditary angioedema, mastalgia, premenstrual syndrome and menorrhagia. Administration orally twice a day.
Since the last update we have not found published data on its excretion in breastmilk or its effect on breastfed infants.
In the absence of data regarding protein binding and the volume of distribution, the known pharmacokinetic data (low molecular weight, high pKa and prolonged half-life) make it likely that it would transfer to milk in amounts which could be significant.
Because of its potential androgenic effect on the infant and prolactin inhibition, it should be avoided during breastfeeding (Hale 2019 p193, Sanofi 2017, AEMPS 2017, Briggs 2015) and replaced by known safe alternatives. (Yeich 2023, Bouillet 2015)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM